Improving Osteoporosis Care through Multi-Modal Interventions: Insights from the University of Alabama (UAB) Center for Education and Research on Therapeutics

Por Curtis, Jeffrey R.
Publicado em 2011

Tumor Necrosis Factor Inhibitors and Infection Complications

Por Crawford, Monica, Curtis, Jeffrey R.
Publicado em 2008

New Methods for Determining Comparative Effectiveness in RA

Por Yun, Huifeng, Curtis, Jeffrey R
Publicado em 2013

Adherence to Osteoporosis Treatments: Room for Improvement

Por Warriner, Amy H., Curtis, Jeffrey R.
Publicado em 2009

The Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care

Por Curtis, Jeffrey R., Singh, Jasvinder A
Publicado em 2011

Management of Osteoporosis among the Elderly with Other Chronic Medical Conditions

Por Curtis, Jeffrey R., Safford, Monika M.
Publicado em 2012

Newest clinical trial results with anti-TNF and non-anti-TNF biologics for Rheumatoid Arthritis

Por Navarro-Millán, Iris, Curtis, Jeffrey R
Publicado em 2013

Predicting Future Response to Certolizumab Pegol in Rheumatoid Arthritis Patients: Features at 12 Weeks Associated With Low Disease Activity at 1 Year

Por Curtis, Jeffrey R., Luijtens, Kristel, Kavanaugh, Arthur
Publicado em 2012

Dyslipidemia and Changes in Lipid Profiles Associated with Rheumatoid Arthritis and Initiation of Anti-TNF Therapy

Por Curtis, Jeffrey R., John, Ani, Baser, Onur
Publicado em 2012

Injection-Site Burning and Stinging in Patients With Rheumatoid Arthritis Using Injectable Biologics

Por Curtis, Jeffrey R, Hobar, Coburn, Hansbrough, Kevin
Publicado em 2010

Long-term Safety Concerns of Antiresorptive Therapy

Por Zhang, Jie, Saag, Kenneth G., Curtis, Jeffrey R.
Publicado no Rheum Dis Clin North Am (2011)

Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic targeting the Interleukin-6 Receptor

Por Navarro-Millán, Iris, Singh, Jasvinder A, Curtis, Jeffrey R
Publicado em 2012

Systematic Review of Tumor Necrosis Factor Inhibitor Discontinuation Studies in Rheumatoid Arthritis

Por Navarro-Millán, Iris, Sattui, Sebastian E., Curtis, Jeffrey R
Publicado em 2013

Vaccinations for Rheumatoid Arthritis

Por Perry, Lisa M., Winthrop, Kevin L., Curtis, Jeffrey R.
Publicado em 2014

The Risk for Cardiovascular Events Associated with Hyperlipdemia among Patients with and Without Rheumatoid Arthritis

Por Nadkarni, Anagha, You, Min, Resuehr, Holly, Curtis, Jeffrey R
Publicado no J Arthritis (2015)

Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs

Por Zhang, Huabin F, Gauthier, Geneviève, Hiscock, Robert, Curtis, Jeffrey R
Publicado em 2014

Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes

Por Singh, Jasvinder A., Ramachandaran, Rekha, Yu, Shaohua, Curtis, Jeffrey R.
Publicado no BMC Cardiovasc Disord (2017)

Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor α antagonists

Por Curtis, Jeffrey R., Xi, Juan, Patkar, Nivedita, Xie, Aiyuan, Saag, Kenneth G.
Publicado em 2007

Adherence with Intravenous Zoledronate and IV Ibandronate in the U.S. Medicare Population

Por Curtis, Jeffrey R, Yun, Huifeng, Matthews, Robert, Saag, Kenneth G., Delzell, Elizabeth
Publicado em 2012

A Multistakeholder Approach to Improving Quality in Rheumatoid Arthritis: Proceedings from the Rheumatoid Arthritis Quality Expert Medical Panel

Por Curtis, Jeffrey R., Kwoh, C. Kent, Rizzoli, Albert J., Welz, John A.
Publicado no Am Health Drug Benefits (2014)